Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Baogong Zhu"'
Publikováno v:
BioTechniques, Vol 43, Iss 3, Pp 354-359 (2007)
In-Fusion™ can join any two pieces of DNA that have a 15-bp overlap at their ends. The result is equivalent to a recombination event at the ends of the DNAs. The 15-bp overlap may be engineered by inclusion in primers used to PCR amplify a segment
Externí odkaz:
https://doaj.org/article/6575d7a712554d2ebe6243cda7f109bb
Autor:
Francesca D'Addio, Takuya Ueno, Michael Clarkson, Baogong Zhu, Andrea Vergani, Gordon J Freeman, Mohamed H Sayegh, Mohammed Javeed I Ansari, Paolo Fiorina, Antje Habicht
Publikováno v:
PLoS ONE, Vol 8, Iss 4, p e60391 (2013)
CD160 is a cell surface molecule expressed by most NK cells and approximately 50% of CD8(+) cytotoxic T lymphocytes. Engagement of CD160 by MHC class-I directly triggers a costimulatory signal to TCR-induced proliferation, cytokine production and cyt
Externí odkaz:
https://doaj.org/article/ba81b9c1e01442a696ba4c636420c149
Autor:
Gordon J. Freeman, Sabina Signoretti, Antonio R. Arulanandam, David F. McDermott, Jie Zhu, Jo Soden, Ping Hua, Baogong Zhu, Maura Sticco-Ivins, Jean-Christophe Pignon, Paul J. Catalano, Opeyemi A. Jegede, Chun-Hau Chen, Samuel S. Freeman, Alyssa N. Klee, Kathleen M. Mahoney, Julie C. Konge, Abdulla Berjis, Rupal S. Bhatt
Blockade of the PD1 pathway is a broadly effective cancer therapy, but additional immune-inhibitory pathways contribute to tumor immune evasion. HERV–H LTR-associating 2 (HHLA2; also known as B7H5 and B7H7) is a member of the B7 family of immunoreg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::332b94b9c7b92f3f2b93b94a42d4aa9f
https://doi.org/10.1158/2326-6066.c.6550380.v1
https://doi.org/10.1158/2326-6066.c.6550380.v1
Autor:
Gordon J. Freeman, Sabina Signoretti, Antonio R. Arulanandam, David F. McDermott, Jie Zhu, Jo Soden, Ping Hua, Baogong Zhu, Maura Sticco-Ivins, Jean-Christophe Pignon, Paul J. Catalano, Opeyemi A. Jegede, Chun-Hau Chen, Samuel S. Freeman, Alyssa N. Klee, Kathleen M. Mahoney, Julie C. Konge, Abdulla Berjis, Rupal S. Bhatt
Supplementary Figures 1-7 and Supplementary Tables 1-2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26775238f169d7ce6bf99bf38eb87c67
https://doi.org/10.1158/2326-6066.22543728
https://doi.org/10.1158/2326-6066.22543728
Supplementary Figures S1-S4 and Table S1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8dcc4ff80384c1fa51cb92bce013956e
https://doi.org/10.1158/2326-6066.22539319.v1
https://doi.org/10.1158/2326-6066.22539319.v1
Autor:
Kathleen M. Mahoney, Seth Maleri, Gordon J. Freeman, Vikram R. Juneja, Xia Bu, Carol Reynolds, Kathleen A. McGuire, Philippe Armand, Jerome Ritz, Sarah R. Klein, Edward A. Greenfield, Ping Hua, Baogong Zhu, Melissa T. Bu, Arlene H. Sharpe
Publikováno v:
Cancer Immunol Res
PD-1 expression marks activated T cells susceptible to PD-1–mediated inhibition but not whether a PD-1–mediated signal is being delivered. Molecular predictors of response to PD-1 immune checkpoint blockade (ICB) are needed. We describe a monoclo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2ce7fd91c667eba6f995c8eb5b61370
https://doi.org/10.1158/2326-6066.cir-21-0493
https://doi.org/10.1158/2326-6066.cir-21-0493
Autor:
Sachet A. Shukla, Edward P. Browne, Hung C. Pham, Thomas Eisenhaure, Vassiliki A. Boussiotis, Catherine J. Wu, Apoorvi Chaudhri, Gordon J. Freeman, Baogong Zhu, Nikolaos Patsoukis, Nir Hacohen, Ping Hua, Xia Bu, William F. Pendergraft, Arnon Arazi, Kathleen M. Mahoney, Edward F. Fritsch
Publikováno v:
Cancer Immunology, Immunotherapy
Targeting immune checkpoint pathways, such as programmed death ligand-1 (PD-L1, also known as CD274 or B7-H1) or its receptor programmed cell death-1 (PD-1) has shown improved survival for patients with numerous types of cancers, not limited to lung
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::937f4b4f00709096a92bda1b008235a4
http://europepmc.org/articles/PMC6426808
http://europepmc.org/articles/PMC6426808
Autor:
Samuel S. Freeman, Jie Zhu, Julie C. Konge, Sabina Signoretti, Jean-Christophe Pignon, Chun-Hau Chen, Baogong Zhu, Kathleen M. Mahoney, Ping Hua, Maura Sticco-Ivins, Opeyemi Jegede, Rupal S. Bhatt, Antonio R. N. Arulanandam, Abdulla Berjis, Gordon J. Freeman, David F. McDermott, Paul J. Catalano, Alyssa N. Klee, Jo Soden
Publikováno v:
Cancer immunology research. 9(2)
Blockade of the PD1 pathway is a broadly effective cancer therapy, but additional immune-inhibitory pathways contribute to tumor immune evasion. HERV–H LTR-associating 2 (HHLA2; also known as B7H5 and B7H7) is a member of the B7 family of immunoreg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ffc89bb8e59ebbd52a36f55fc2e8025
https://pubmed.ncbi.nlm.nih.gov/33536266
https://pubmed.ncbi.nlm.nih.gov/33536266
Publikováno v:
Cancer Immunology Research. 6:921-929
Programmed death ligand 1 (PD-L1)–mediated immunosuppression regulates peripheral tolerance and is often co-opted by tumors to evade immune attack. PD-L1 binds to PD-1 but also binds to B7-1 (CD80) to regulate T-cell function. The binding interacti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b5e7ecd8394a10c626e01f0597a34e3
https://doi.org/10.1158/2326-6066.cir-17-0316
https://doi.org/10.1158/2326-6066.cir-17-0316
Autor:
Gordon J. Freeman, Baogong Zhu, Antonio R. N. Arulanandam, Alyssa N. Klee, Rupal S. Bhatt, Kathleen M. Mahoney
Publikováno v:
Cancer Research. 80:926-926
Cancer immunotherapies blocking immuno-inhibitory pathways have become a successful treatment method in the last decade. HHLA2 (human endogenous retrovirus-H long terminal repeat-associating protein 2) is a B7 family member and ligand that is often e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b31c2742f913f28ccae65e7f474928f
https://doi.org/10.1158/1538-7445.am2020-926
https://doi.org/10.1158/1538-7445.am2020-926